If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-06. Numbers and descriptions here follow the published literature rather than marketing material.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
BlueDragon - Proprietary .NET-based CFML engine and free open source Java-based CFML engine (Open BlueDragon). Coral Web Builder IgniteFusion OpenBD - The open source version of BlueDragon was released as Open BlueDragon (OpenBD) in December 2008. Railo - Free, open source CFML engine. It comes in three main product editions, and other versions. SmithProject The argument can be made that ColdFusion is even less platform-bound than raw Java EE or .NET, simply because ColdFusion will run on top of a .NET app server (New Atlanta), or on top of any servlet container or Java EE application server (JRun, WebSphere, JBoss, Geronimo, Tomcat, Resin Server, Jetty (web server), etc.). In theory, a ColdFusion application could be moved unchanged from a Java EE application server to a .NET application server.
==== Bacterial proteasomes ==== Actinobacteria have acquired a proteasome degradation pathway, including its own 20S core particle and a AAA protein motor, MPA (mycobacterial proteasome activator). Unlike the base subcomplex of the 19S, MPA is a homohexameric motor complex, containing the ATPase sites, a tandem (oligosaccharide/oligonucleotide-binding) OB ring, and Coiled coils that extend off N-termini off the OB ring. The C-terminus contains HBXY motifs that contact the 20S core particle in a similar way as with other regulatory particles. Targeting to MPA requires a prokaryotic protein, Prokaryotic ubiquitin-like protein (or Pup) that functions as ubiquitin as a tag that can be attached to a protein substrate, though the structure of Pup is unrelated to that of ubiquitin. Once attached, a puplyated protein can be targeted to MPA through the coiled-coil and can be directed through the AAA motor into the 20S for degradation.
electrophile Any atom or molecule which can accept an electron pair. Most electrophiles carry a net positive charge, include an atom carrying a partial positive charge, or include a neutral atom that does not have a complete octet of electrons, and therefore they attract electron-rich regions of other species; an electrophile with vacant orbitals can accept an electron pair donated by a nucleophile, creating a chemical bond between the two species. Because they accept electrons, electrophiles are Lewis acids by definition.
Erratic dimming and strong infrared emission are attributed to hot debris produced by the impact passing in front of the star. 12 March – An international team reports the first direct measurements of the nanomechanical properties of lithium dendrites, microscopic needle-like structures that can form inside lithium batteries and cause them to short circuit or catch fire. The study finds that dendrites are strengthened by a solid electrolyte interphase layer, making them brittle and capable of penetrating battery separators, providing new insight into battery degradation and safety risks. 17 March – Physicists at CERN's LHCb experiment report the discovery of the doubly charmed baryon Ξcc⁺. The particle, containing two charm quarks and one down quark, is detected with high statistical significance and resolves a long-standing discrepancy from earlier experimental results. 18 March – Charles H. Bennett and Gilles Brassard are awarded the 2025 Turing Award for their work in quantum information science. 20 March – Scientists from Great Ormond Street Hospital and University College London report the creation of the first lab‑grown oesophagus, and show it can safely replace a full section of the organ and restore normal function, including swallowing, in a growing animal without the need for immunosuppression. 24 March Antimatter particles are transported by road for the first time, to assess their stability during transit. An estimated 100 to 1,000 antiprotons are carried in a Penning trap across a distance of five kilometres in Switzerland.
Sources: en.wikipedia.org
== Applications of commercially synthesized peptides == Biologically active peptides have been integrated into a growing number of active pharmaceutical ingredients (API’s) as well as standalone products such as vasopressin, gonadorelin, leuprolide, and goserelin. Completion of the Human Genome Project resulted in the identification of approximately 30,000 proteins encoded in the human genome and provided many more new target molecules for biomedical researchers to explore. To investigate the possibility of increasing the native potency of a given peptide or protein using a rational design approach, small and large amounts of peptides are needed, Some in the milligram scale. Once a desired activity or potency is identified, larger scale synthesis is need. For this, gram to multi-gram scale may be needed in order to initiate small animal studies. Often, after successful validation, an even larger scale of synthesis may be desired. These can range in scale from hundreds of grams to multi-kilo amounts.
A tooth from what is now documented as a Tyrannosaurus rex was found in July 1874 upon South Table Mountain (Colorado) by Jarvis Hall student Peter T. Dotson under the auspices of Arthur Lakes near Golden, Colorado, in sediments belonging to the Denver Formation. In the early 1890s, John Bell Hatcher collected postcranial elements in eastern Wyoming. The fossils were believed to be from the large species Ornithomimus grandis (now Deinodon) but are now considered T. rex remains. In 1892, Edward Drinker Cope found two vertebral fragments of a large dinosaur. Cope believed the fragments belonged to an "agathaumid" (ceratopsid) dinosaur, and named them Manospondylus gigas, meaning "giant porous vertebra", in reference to the numerous openings for blood vessels he found in the bone. The M. gigas remains were, in 1907, identified by Hatcher as those of a theropod rather than a ceratopsid. Henry Fairfield Osborn recognized the similarity between Manospondylus gigas and T. rex as early as 1917, by which time the second vertebra had been lost. Owing to the fragmentary nature of the Manospondylus vertebrae, Osborn did not synonymize the two genera, instead considering the older genus indeterminate. In June 2000, the Black Hills Institute found around 10% of a Tyrannosaurus skeleton (BHI 6248) at a site that might have been the original M. gigas locality. While Larson initially considered this specimen as the same animal as the M. gigas holotype and suggested that it would take priority over T. rex, other researchers including Christopher Brochu remained skeptical that the name T.
S + O2 → SO2 (sulfur dioxide) 2 SO2 + O2 → 2 SO3 (sulfur trioxide) Many other sulfur oxides are observed including the sulfur-rich oxides sulfur monoxide, disulfur monoxide, disulfur dioxides, and higher oxides containing peroxo groups.
=== Fashion === Bobbi Brown (born 1957), makeup artist Lisa Lindahl (born 1948), writer, artist, activist and inventor Jack McCollough (born 1978), fashion designer; co-creator of Proenza Schouler Polly Smith (born 1949), designer, inventor and creator of the sports bra, who was a costume designer for The Muppet Show and Sesame Street Louise Vyent, Dutch-born fashion model and portrait photographer
=== Regulatory scrutiny and international expansion (2025–2026) === In June 2025, Hims & Hers acquired the London-based European digital health platform ZAVA for undisclosed cash consideration, extending the company's presence into Germany, France, and Ireland alongside deeper reach into the United Kingdom. In August 2025, Bloomberg reported that the Federal Trade Commission had been investigating the company's advertising claims and subscription cancellation practices for more than a year. On September 9, 2025, the FDA sent Hims & Hers a warning letter as part of a broader enforcement effort targeting more than 100 drug advertisers, faulting the company for statements on its website claiming that its compounded products contained "the same active ingredient" as FDA-approved Ozempic and Wegovy. On February 5, 2026, Hims & Hers introduced a compounded oral semaglutide pill for the first month, undercutting Novo Nordisk's newly approved branded oral Wegovy pill. Novo Nordisk announced its intention to sue the company for patent infringement related to U.S. Patent No. 8,129,343, which protects the semaglutide molecule until December 2031. On February 7, 2026, Hims & Hers announced it would withdraw the compounded oral pill from its platform. Novo Nordisk formally filed the patent infringement suit in the United States District Court for the District of Delaware on February 9, 2026.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.